Compare Diageo plc (DEO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Novo Nordisk A/S — how do they compare? Diageo plc trades at $87.58 (market cap $47.67B), while Novo Nordisk A/S trades at $38.2 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3.5× Diageo plc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Novo Nordisk A/S for 116 Days on average.
| DEO | NVO | |
|---|---|---|
Market Cap | $47.67B | $165.31B |
Volume | 893,372 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $63.98 |
52-Week Low | $72.47 | $35.29 |
Typical Hold Time | 66 Days | 116 Days |
Enterprise Value | $68.09B | $179.56B |
Dividend Yield | 2.3% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $84.73, down 0.06% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 59.47% gross margin and has beaten EPS estimates in the last three quarters. Recent news highlights marketing initiatives and a CFO transition planned for 2027. The balance sheet shows $2.65B in cash against $23.75B in total debt, with a debt-to-asset ratio improving to 48.05% in 2026.
The outlook is mixed: analyst consensus leans bullish (49% buy ratings) with a focus on the US turnaround plan, but 2026 projections show declining revenue and net income. Key risks include execution of the restructuring, competitive pressures, and regulatory challenges in markets like India. The stock offers income via dividends but faces near-term fundamental headwinds.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
